263 related articles for article (PubMed ID: 32009039)
1. [Induction of Anti-PEG Immune Responses by PEGylation of Proteins].
Shimizu T; Ishima Y; Ishida T
Yakugaku Zasshi; 2020; 140(2):163-169. PubMed ID: 32009039
[TBL] [Abstract][Full Text] [Related]
2. Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives.
Gaballa SA; Shimizu T; Ando H; Takata H; Emam SE; Ramadan E; Naguib YW; Mady FM; Khaled KA; Ishida T
J Pharm Sci; 2024 Mar; 113(3):555-578. PubMed ID: 37931786
[TBL] [Abstract][Full Text] [Related]
3. Antibodies against polyethylene glycol in human blood: A literature review.
Hong L; Wang Z; Wei X; Shi J; Li C
J Pharmacol Toxicol Methods; 2020; 102():106678. PubMed ID: 31981619
[TBL] [Abstract][Full Text] [Related]
4. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
[TBL] [Abstract][Full Text] [Related]
5. Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
Gaballa SA; Shimizu T; Takata H; Ando H; Ibrahim M; Emam SE; Amorim Matsuo NC; Kim Y; Naguib YW; Mady FM; Khaled KA; Ishida T
Mol Pharm; 2024 Feb; 21(2):622-632. PubMed ID: 38273445
[TBL] [Abstract][Full Text] [Related]
6. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM
Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791
[TBL] [Abstract][Full Text] [Related]
7. Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice.
McSweeney MD; Shen L; DeWalle AC; Joiner JB; Ciociola EC; Raghuwanshi D; Macauley MS; Lai SK
J Control Release; 2021 Jan; 329():774-781. PubMed ID: 33038448
[TBL] [Abstract][Full Text] [Related]
8. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response.
Shimizu T; Ichihara M; Yoshioka Y; Ishida T; Nakagawa S; Kiwada H
Biol Pharm Bull; 2012; 35(8):1336-42. PubMed ID: 22863934
[TBL] [Abstract][Full Text] [Related]
9. Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.
Zhang P; Sun F; Liu S; Jiang S
J Control Release; 2016 Dec; 244(Pt B):184-193. PubMed ID: 27369864
[TBL] [Abstract][Full Text] [Related]
10. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route.
Takata H; Shimizu T; Yamade R; Elsadek NE; Emam SE; Ando H; Ishima Y; Ishida T
J Control Release; 2023 Aug; 360():285-292. PubMed ID: 37355210
[TBL] [Abstract][Full Text] [Related]
11. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies.
Chen BM; Cheng TL; Roffler SR
ACS Nano; 2021 Sep; 15(9):14022-14048. PubMed ID: 34469112
[TBL] [Abstract][Full Text] [Related]
12. Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice.
Elsadek NE; Hondo E; Shimizu T; Takata H; Abu Lila AS; Emam SE; Ando H; Ishima Y; Ishida T
Mol Pharm; 2020 Aug; 17(8):2964-2970. PubMed ID: 32519877
[TBL] [Abstract][Full Text] [Related]
13. Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture.
Lin YC; Chen BM; Tran TTM; Chang TC; Al-Qaisi TS; Roffler SR
J Control Release; 2023 Feb; 354():354-367. PubMed ID: 36641121
[TBL] [Abstract][Full Text] [Related]
14. Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG.
McSweeney MD; Price LSL; Wessler T; Ciociola EC; Herity LB; Piscitelli JA; DeWalle AC; Harris TN; Chan AKP; Saw RS; Hu P; Jennette JC; Forest MG; Cao Y; Montgomery SA; Zamboni WC; Lai SK
J Control Release; 2019 Oct; 311-312():138-146. PubMed ID: 31454530
[TBL] [Abstract][Full Text] [Related]
15. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
[TBL] [Abstract][Full Text] [Related]
16. Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM via a T Cell-Dependent Mechanism.
Elsadek NE; Emam SE; Abu Lila AS; Shimizu T; Ando H; Ishima Y; Ishida T
Biol Pharm Bull; 2020; 43(9):1393-1397. PubMed ID: 32879214
[TBL] [Abstract][Full Text] [Related]
17. Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice.
Poppenborg SM; Wittmann J; Walther W; Brandenburg G; Krähmer R; Baumgart J; Leenders F
Eur J Pharm Sci; 2016 Aug; 91():122-30. PubMed ID: 27292820
[TBL] [Abstract][Full Text] [Related]
18. The immunogenicity of polyethylene glycol: facts and fiction.
Schellekens H; Hennink WE; Brinks V
Pharm Res; 2013 Jul; 30(7):1729-34. PubMed ID: 23673554
[TBL] [Abstract][Full Text] [Related]
19. Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity.
Mima Y; Abu Lila AS; Shimizu T; Ukawa M; Ando H; Kurata Y; Ishida T
J Control Release; 2017 Mar; 250():20-26. PubMed ID: 28179196
[TBL] [Abstract][Full Text] [Related]
20. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products.
Ibrahim M; Ramadan E; Elsadek NE; Emam SE; Shimizu T; Ando H; Ishima Y; Elgarhy OH; Sarhan HA; Hussein AK; Ishida T
J Control Release; 2022 Nov; 351():215-230. PubMed ID: 36165835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
